688488 Jiangsu Aidea Pharmaceutical
- 8.38
- -0.07-0.83%
Jiangsu Aidea Pharmaceutical News
Notice of Subscription Agreement and Related Party Transaction Signed by Jiangsu Aidea Pharmaceuticals with Specific Party Subject to Certain Conditions
Summary of Acquisition Report of Jiangsu Aidea Pharmaceutical Co., Ltd.
Announcement from Jiangsu Aidea Pharmaceutical regarding Mr. Fu Heliang's issuance of A-share stocks to specific individuals in the company for the year 2024
Legal Opinion on the Second Extraordinary General Meeting of Shareholders of Jiangsu Aidea Pharmaceutical Co., Ltd. in 2024 by Jiangsu Century Tongren Law Firm.
Announcement of Resolutions of the Second Extraordinary General Meeting of Shareholders of Jiangsu Aidea Pharmaceutical Co., Ltd. in 2024.
Jiangsu Aidea Pharmaceutical's second interim shareholder meeting materials in 2024.
Notice on holding the second extraordinary shareholders' meeting of Jiangsu Aidea Pharmaceutical in 2024.
Jiangsu Aidea Pharmaceutical's board of directors has released a statement regarding the stock price fluctuations prior to the first disclosure of the restructuring plan.
Explanation of Jiangsu Aidea Pharmaceutical's board of directors on the evaluation of the independence of the institutions, the reasonableness of the evaluation assumptions, the relevance of the evaluation methods and evaluation objectives, and the fairness of the evaluation pricing.
Announcement from Jiangsu Aidea Pharmaceutical Co., Ltd. regarding dilution of immediate returns, filling measures, and related subject commitments on this trade.
Announcement of Jiangsu Aidea Pharmaceutical regarding the temporary non-convening of a shareholder meeting.
The board of directors of Jiangsu Aidea Pharmaceutical Co., Ltd. stated that this major asset restructuring complies with Article 20 of the Continuous Supervision Measures for Listed Companies on the Science and Technology Innovation Board (Trial), Article 8 of the Shanghai Stock Exchange's Review Rules for Major Asset Restructuring of Listed Companies, and Article 11.2 of the Listing Rules for Stocks on the Science and Technology Innovation Board of Shanghai Stock Exchange.
Voluntary Disclosure Announcement of Jiangsu Aidea Pharmaceutical regarding the Approval Notification of the Listing Application for Active Pharmaceutical Ingredient of Enolivir.
Eddy Pharmaceuticals Announces Response to Regulatory Inquiry Letter on the Information Disclosure of the 2023 Annual Report
Announcement of Resolutions of Eddy Pharmaceutical's 2023 Annual General Meeting of Shareholders
Legal Opinion of Jiangsu Century Tongren Law Firm on the 2023 Annual General Meeting of Shareholders of Jiangsu Eddy Pharmaceutical Co., Ltd.
Eddy Pharmaceuticals 2023 Annual Shareholders' Meeting Meeting Materials
Eddy Pharmaceuticals 2024 “Improve Quality, Increase Efficiency, and Value Rewards” Action Plan
Eddy Pharmaceutical's Announcement on Requesting the Shareholders' Meeting to Authorize the Board of Directors to Issue Shares to Specific Targets through Simple Procedures
Adi Pharmaceutical\'s Notice on Convening the 2023 Annual General Meeting of Shareholders
Analysis
Price Target
No Data
